	US 11,986,553 B2
	Multi-component injection
Xiaoqing Yao, Wuqing Tianjin (CN); Changhai Sun, Wuqing Tianjin (CN); Kai Dong, Wuqing Tianjin (CN); Chuan Li, Wuqing Tianjin (CN); Guiping Zhang, Wuqing Tianjin (CN); Tianhao Dong, Wuqing Tianjin (CN); Jing Cao, Wuqing Tianjin (CN); Qiyun Wang, Wuqing Tianjin (CN); Xianjun Li, Wuqing Tianjin (CN); Junmin Gao, Wuqing Tianjin (CN); and Mingzhen Sun, Wuqing Tianjin (CN)
Assigned to TIANJIN CHASE SUN PHARMACEUTICAL CO. LTD, Waging Tianjin (CN)
Filed by TIANJIN CHASE SUN PHARMACEUTICAL CO. LTD, Wuqing Tianjin (CN)
Filed on Apr. 20, 2021, as Appl. No. 17/235,126.
Application 17/235,126 is a division of application No. 15/737,808, previously published as PCT/CN2017/089695, filed on Jun. 23, 2017.
Claims priority of application No. 201611232221.7 (CN), filed on Dec. 28, 2016.
Prior Publication US 2021/0346281 A1, Nov. 11, 2021
Int. Cl. A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/192 (2006.01); A61K 31/194 (2006.01); A61K 31/198 (2006.01); A61K 31/235 (2006.01); A61K 31/343 (2006.01); A61K 31/353 (2006.01); A61K 31/513 (2006.01); A61K 31/52 (2006.01); A61K 31/7048 (2006.01); A61K 31/7064 (2006.01); A61K 31/7076 (2006.01); A61K 31/708 (2006.01); A61K 36/232 (2006.01); A61K 36/236 (2006.01); A61K 36/28 (2006.01); A61K 36/286 (2006.01); A61K 36/537 (2006.01); A61K 36/65 (2006.01); A61K 47/26 (2006.01); A61P 31/04 (2006.01)

CPC A61K 9/0019 (2013.01) [A61K 9/08 (2013.01); A61K 31/192 (2013.01); A61K 31/194 (2013.01); A61K 31/198 (2013.01); A61K 31/235 (2013.01); A61K 31/343 (2013.01); A61K 31/353 (2013.01); A61K 31/513 (2013.01); A61K 31/52 (2013.01); A61K 31/7048 (2013.01); A61K 31/7064 (2013.01); A61K 31/7076 (2013.01); A61K 31/708 (2013.01); A61K 36/232 (2013.01); A61K 36/236 (2013.01); A61K 36/28 (2013.01); A61K 36/286 (2013.01); A61K 36/537 (2013.01); A61K 36/65 (2013.01); A61K 47/26 (2013.01); A61P 31/04 (2018.01); A61K 2236/331 (2013.01); A61K 2236/333 (2013.01); A61K 2236/37 (2013.01); A61K 2236/39 (2013.01); A61K 2236/53 (2013.01)]

11 Claims

1. A method for treating sepsis in a subject in need thereof comprising administering to the subject a multi-component injection, wherein the multi-component injection comprises albiflorin std, paeoniflorin, Oxypaeoniflorin, Benzoylpaeoniflorin, Benzoyloxypaeoniflorin, Mudanpioside J, galloylpaeoniflorin, Mudanpioside C, benzoic acid, gallic acid, ethyl gallate, catechin, Kaempferol-3-0-glucoside, scutellarin, quercetin-3-0-glucoside, Kaempferol-3-0-rutinoside, Kaempferol-3-0-sophoroside, quercetin-3-0-rutinoside, Hydroxysafflor yellow A, uracil, adenine, phenylalanine, uridine, adenosine, guanosine, butanedioic acid, p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, chlorogenic acid, senkyunolide I (42), senkyunolide H, senkyunolide N, open-loop senkyunolide I, senkyunolide G, 3-hydroxyl-3-butylphthalide, senkyunolide A, and ferulaic acid.